Cargando…

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib

BACKGROUND: Recently, we have shown that the ATP-binding cassette (ABC) transporter ABCB1 interferes with the anti-cancer activity of the pan-aurora kinase inhibitor tozasertib (VX680, MK-0457) but not of the aurora kinase A and B inhibitor alisertib (MLN8237). Preliminary data had suggested tozaser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michaelis, Martin, Selt, Florian, Rothweiler, Florian, Wiese, Michael, Cinatl, Jindrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587578/ https://www.ncbi.nlm.nih.gov/pubmed/26415506 http://dx.doi.org/10.1186/s13104-015-1405-4

Ejemplares similares

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
por: Michaelis, Martin, et al.
Publicado: (2014)

RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680)
por: Martens, Sofie, et al.
Publicado: (2018)

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression
por: Michaelis, Martin, et al.
Publicado: (2014)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
por: Pitts, Todd M., et al.
Publicado: (2016)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status
por: Michaelis, Martin, et al.
Publicado: (2015)

Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
por: Wang, Lihong, et al.
Publicado: (2017)

Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
por: Niu, Huifeng, et al.
Publicado: (2015)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
por: Fathi, Amir T., et al.
Publicado: (2017)

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases
por: Jane, Esther P., et al.
Publicado: (2021)

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor
por: Niu, Huifeng, et al.
Publicado: (2017)

Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A
por: Michaelis, Martin, et al.
Publicado: (2014)

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
por: Goldberg, Stuart L., et al.
Publicado: (2014)

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells
por: Ding, Yong-Hui, et al.
Publicado: (2015)

Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach
por: Sarin, Navin, et al.
Publicado: (2018)

ABCB1 as predominant resistance mechanism in cells with acquired SNS-032 resistance
por: Löschmann, Nadine, et al.
Publicado: (2016)

Investigation of the influence of EPs(®) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses
por: Michaelis, Martin, et al.
Publicado: (2011)

Correlation of inflammatory and proangiogenic cytokines from undiluted vitreous samples with spectral domain OCT scans, in untreated branch retinal vein occlusion
por: Pfister, Marcel, et al.
Publicado: (2013)

Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport
por: Michaelis, Martin, et al.
Publicado: (2016)

BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells
por: Das, Chandan Kanta, et al.
Publicado: (2018)

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells
por: Yuan, Chun-Xiu, et al.
Publicado: (2015)

Inhibition of Aurora Kinase A by Alisertib Reduces Cell Proliferation and Induces Apoptosis and Autophagy in HuH-6 Human Hepatoblastoma Cells
por: Tan, Jingyi, et al.
Publicado: (2020)

Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling
por: Shang, Yuan-Yuan, et al.
Publicado: (2017)

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting
por: Michaelis, Martin, et al.
Publicado: (2020)

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020)

Increased HRD score in cisplatin resistant penile cancer cells
por: Winkelmann, Ria, et al.
Publicado: (2022)

Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G(2)/M cell cycle arrest
por: Sarin, Navin, et al.
Publicado: (2017)

Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics()()
por: Vallo, Stefan, et al.
Publicado: (2015)

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation
por: Vogel, Jens-Uwe, et al.
Publicado: (2019)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
por: Gavriilidis, Paschalis, et al.
Publicado: (2015)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells
por: Vallo, Stefan, et al.
Publicado: (2017)

Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC
por: Gohlke, Linus, et al.
Publicado: (2023)

Aurora kinase inhibitors: Progress towards the clinic
por: Kollareddy, Madhu, et al.
Publicado: (2012)

Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells
por: Tsaur, Igor, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o411p9nngujq0rdm7tmduaepm6